-
公开(公告)号：US20240400994A1
公开(公告)日：2024-12-05
申请号：US18798138
申请日：2024-08-08
Applicant: Allergan Sales, LLC
Inventor： Patrick Nido
Abstract: Compositions that include extracellular matrix material and/or conditioned medium obtained from cells cultured under hypoxic conditions in a suitable growth medium and methods for producing the compositions. The compositions may also include botanicals, peptides, seed extracts, marine extracts and/or bacterial ferments. The compositions may be used to repair and regeneration of skin tissue.
-
公开(公告)号：US12133870B2
公开(公告)日：2024-11-05
申请号：US16822746
申请日：2020-03-18
Applicant: SPINALCYTE LLC
Inventor： Pete O'Heeron , Thomas Ichim
Abstract: Disclosed are methods and compositions comprising fibroblasts and/or products derived thereof for the inhibition and/or treatment of addiction of any kind, such as opioid addiction. In some embodiments, methods comprise treating a patient addicted to opioids by administering a fibroblast population at a concentration sufficient for suppression of addiction-associated brain damage. In some embodiments, the fibroblasts express CD31 and/or CD73 markers. In some embodiments, fibroblasts are used to endow neuronal regeneration in order to overcome changes in the brain associated with addiction. Some embodiments relate to the stimulation of hippocampal regeneration subsequent to addiction induced damage.
-
公开(公告)号：US20240293469A1
公开(公告)日：2024-09-05
申请号：US18659876
申请日：2024-05-09
Applicant: Figene, LLC
Inventor： Pete O'Heeron , Thomas Ichim
CPC classification number: A61K35/33 , A61K39/0011 , A61K45/06 , A61P35/00 , C07K14/7158 , C12N5/0656 , C12N7/00 , A61K2039/585 , C12N2500/02 , C12N2710/24134 , C12N2710/24171
Abstract: Embodiments of the disclosure encompass methods and compositions for treatment of cancer utilizing fibroblasts that have been modified to enhance their ability to deliver one or more anti-cancer agents to an individual in need thereof. In particular embodiments, the fibroblasts have been modified to express one or more chemokine receptors and/or have been exposed to hypoxia to enhance their ability to home to cancer cells. In specific cases the modified fibroblasts are engineered to encompass an oncolytic virus as a tumor inhibitory agent.
-
公开(公告)号：US20240261336A1
公开(公告)日：2024-08-08
申请号：US18618017
申请日：2024-03-27
Applicant: FIGENE, LLC
Inventor： Pete O'HEERON , Thomas Ichim
IPC: A61K35/33 , A61K31/522 , A61K31/56 , A61K45/06
CPC classification number: A61K35/33 , A61K31/522 , A61K31/56 , A61K45/06
Abstract: Embodiments of the disclosure include methods and compositions for treatment of lung disease, including at least chronic obstructive pulmonary disease (COPD). In particular cases, fibroblasts (including activated fibroblasts) and/or exosomes thereof are provided to an individual for the treatment of COPD. In particular cases the fibroblasts are activated and/or express one or more particular markers.
-
5.发明公开公开(公告)号：US20240148795A1
公开(公告)日：2024-05-09
申请号：US18548803
申请日：2022-03-03
Applicant: METCELA INC.
Inventor： Takahiro IWAMIYA
Abstract: A fibroblast highly expressing ADM and/or HHEX has been found as a cell having lymphangiogenesis ability, and a procedure for treating fibrosis, a procedure for ameliorating a condition of lymphangiogenesis ability reduced, and procedures for modulating homeostasis of a tissue fluid, transport of lipid and/or vitamin, and immunological surveillance, and for treating organ failure, by use of a pharmaceutical composition including the fibroblast, have been found. In addition, it has been found that an adult-derived fibroblast highly expressing ADM and increasing expression of VCAM-1 is obtained by culturing a human fibroblast with a medium to which TNF-α and IL-4 are added and it has been found that a fibroblast highly expressing ADM is provided, and a procedure for treating a pulmonary disease by use of the fibroblast has been found.
-
Patent Agency Ranking
公开(公告)号：US11903974B2
公开(公告)日：2024-02-20
申请号：US15779736
申请日：2016-11-30
Inventor： Geoffrey A. von Maltzahn , John Miles Milwid , Michael Travis Mee , Jacob Rosenblum Rubens , David Chess , Kyle Marvin Trudeau , Kiana Mahdaviani , Jacob Feala , James D. McCully , Douglas B. Cowan
IPC: A61K35/35 , A61K35/34 , A61K35/14 , A61K35/19 , A61K38/17 , A61K35/33 , G01N33/15 , C12N15/87 , A61K35/12 , A61P3/00 , A61K9/00
CPC classification number: A61K35/35 , A61K35/12 , A61K35/14 , A61K35/19 , A61K35/33 , A61K35/34 , A61K38/1709 , A61P3/00 , C12N15/87 , G01N33/15 , A61K9/0029
Abstract: Therapeutic chondrisome compositions and related methods are described.
-
公开(公告)号：US11878037B2
公开(公告)日：2024-01-23
申请号：US16887720
申请日：2020-05-29
Applicant: Figene, LLC
Inventor： Pete O'Heeron , Thomas Ichim
CPC classification number: A61K35/33 , C12N5/0656 , C12N2501/22 , C12N2501/26
Abstract: Described are means, methods, and compositions useful for treatment of multiple sclerosis through the utilization of fibroblasts and/or derivatives thereof to concurrently stimulate regenerative processes while inducing a protolerogenic immune modulatory program. In certain embodiments, fibroblasts are selected for the concurrent properties of immune modulation and regeneration by enrichment for CD73 expressing fibroblasts. In particular embodiments, stimulation of regeneration implies activation of endogenous neural progenitor cells. In some embodiments, stimulation of regeneration implies induction of remyelination. The utilization of fibroblasts as a superior source for immune modulation, prevention of immune mediated pathology, and activation of T regulatory cells is provided within the context of multiple sclerosis.
-
公开(公告)号：US20230407259A1
公开(公告)日：2023-12-21
申请号：US18345022
申请日：2023-06-30
Applicant: SPINALCYTE, LLC
Inventor： Pete O'HEERON , Thomas ICHIM
CPC classification number: C12N5/0656 , A61K35/33 , C12N2500/02 , C12N2501/065 , C12N2501/105 , C12N2502/45
Abstract: Embodiments of the disclosure include methods and compositions for disc repair in a mammal using conditioned media (and/or one or more components therefrom) from fibroblasts that have been de-differentiated and cultured optionally with one or more particular conditions and/or compositions. In specific cases, fibroblasts that have been de-differentiated are exposed to hypoxia, histone deacetylase inhibitor(s), DNA methyltransferase inhibitor(s), or a combination thereof, and the conditioned media therefrom is provided in an effective amount to an individual.
-
公开(公告)号：US20230313222A1
公开(公告)日：2023-10-05
申请号：US18300994
申请日：2023-04-14
Applicant: LONZA WALKERSVILLE, INC.
Inventor： Eytan ABRAHAM , Thomas PAYNE , Robert J. YOUNG , Inbar FRIEDRICH BEN NUN
CPC classification number: C12N15/85 , C12N5/0696 , A61K35/15 , A61K35/33 , A61K35/51 , G01N33/5073 , A61K35/12 , C12N2510/00 , C12N2501/603 , C12N2506/11 , C12N2501/604 , C12N2501/608 , C12N2501/602 , C12N2501/606 , C12N2501/40
Abstract: The current disclosure provides methods for reprogramming mammalian somatic cells by regulating the expression of endogenous cellular genes. Cellular reprogramming of somatic cells can be induced by activating the transcription of embryonic stem cell-associated genes (e.g., oct3/4) and suppressing the transcription of somatic cell-specific and/or cell death-associated genes. The endogenous transcription machinery can be modulated using synthetic transcription factors (activators and suppressors), to allow for faster, and more efficient nuclear reprogramming under conditions amenable for clinical and commercial applications. The current disclosure further provides cells obtained from such methods, along with therapeutic methods for using such cells for the treatment of diseases amendable to stem cell therapy, as well as kits for such uses.
-
公开(公告)号：US20230203487A1
公开(公告)日：2023-06-29
申请号：US17998857
申请日：2021-05-17
Applicant: Cedars-Sinai Medical Center
Inventor： Eduardo Marbán , Alessandra Ciullo , Ahmed G. Ibrahim
IPC: C12N15/113 , A61P9/10 , A61P11/00 , A61K35/33 , A61K31/7105 , A61K35/28
CPC classification number: C12N15/113 , A61P9/10 , A61P11/00 , A61K35/33 , A61K31/7105 , A61K35/28 , C12N2310/14 , C12N2320/35 , C12N2320/32 , C12N2310/141
Abstract: Provided herein are PIWI-interacting RNA (piRNA) derived from therapeutic exosomes, and methods of use thereof to treat a condition requiring tissue repair and/or regeneration. Conditions treated by the exosome-derived piRNAs and/or exosomes carrying the same include, in some embodiments, ischemic injury and/or tissue fibrosis. Also provided are therapeutic compositions comprising exosome-derived piRNA and a pharmaceutically acceptable excipient.
-
-
-
-
-
-
-
-
-
Search Results
420
records
(took 0.039 seconds)
